

## REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of \_\_\_\_\_

Application Number

09/256388

Filed

2-24-99

Art Unit

Examiner

Paper No. \_\_\_\_\_

Assistant Commissioner for Patents  
Washington, DC 20231

1. ☐ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:

United States Patent Application Publication No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_,

United States Patent Number \_\_\_\_\_, column \_\_\_\_\_, line \_\_\_\_\_, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. \_\_\_\_\_, paper No. \_\_\_\_\_, page \_\_\_\_\_, line \_\_\_\_\_.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Deborah L Harris  
Signature

7-28-03

Date

Deborah L Harris  
Typed or printed name

FOR PTO USE ONLY

Approved by: \_\_\_\_\_

(Initials)

Unit: \_\_\_\_\_

Pm R



**United States Patent** [19]  
**Tobinick et al.**

[11] **Patent Number:** **6,015,557**  
[45] **Date of Patent:** **Jan. 18, 2000**

[54] **TUMOR NECROSIS FACTOR ANTAGONISTS  
FOR THE TREATMENT OF  
NEUROLOGICAL DISORDERS**

5,656,272 8/1997 Le et al. .  
5,795,967 8/1998 Aggarwal et al. .

[76] **Inventors:** Edward L. Tobinick; Arthur Jerome  
Tobinick, both of 100 UCLA Medical  
Plz., Suite 205, Los Angeles, Calif.  
90024-6903

*Primary Examiner*—William R. A. Jarvis  
*Attorney, Agent, or Firm*—Ezra Sutton

[21] **Appl. No.:** 09/275,070  
[22] **Filed:** Mar. 23, 1999

[57] **ABSTRACT**

**Related U.S. Application Data**

[63] Continuation-in-part of application No. 09/256,388, Feb. 24,  
1999, abandoned.  
[51] **Int. Cl.<sup>7</sup>** ..... A61K 39/395; A61K 31/495;  
A61K 31/50; A61K 31/42  
[52] **U.S. Cl.** ..... 424/134.1; 514/249; 514/378  
[58] **Field of Search** ..... 424/134.1; 514/249,  
514/378

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.

Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

[56] **References Cited**  
**U.S. PATENT DOCUMENTS**

5,605,690 2/1997 Jacobs et al. .

**47 Claims, No Drawings**